Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Loses Bid For India Patent On New Prilosec Formulation (India)

This article was originally published in PharmAsia News

Executive Summary

Indian authorities have denied AstraZeneca a patent for a new formulation of its Prilosec (omeprazole) drug for treating ulcers. Indian drug maker Torrent Pharma had filed opposition to the patent. The Delhi patent office said it rejected the patent requiest because the new formulation did not provide enhanced therapeutic efficacy to the already-patented formulation. Generics of the drug have been available in India for several years. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts